Organization
University of Okahoma Health Sciences Center
5 abstracts
Abstract
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.Org: University of Okahoma Health Sciences Center,
Abstract
Correlation of stress, depression, sleep, and pain with race and body mass index (BMI): Secondary analysis from Alliance A011502.Org: Roswell Park Comprehensive Cancer Center, Mayo Clinic, Channing Laboratory, Johns Hopkins Kimmel Cancer Center, Sweetwater Regional Cancer Center,
Abstract
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.Org: University of Okahoma Health Sciences Center, Carolina BioOncology Institute, Sarah Cannon Research Institute/Tennessee Oncology, University of Michigan, START Midwest, Grand Rapids, MI,
Abstract
Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.Org: Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Foundation Medicine, Inc., Cambridge, MA, Stephenson Cancer Center at the University of Oklahoma HSC, University of Okahoma Health Sciences Center,
Abstract
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers).Org: University of Texas MD Anderson Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,